Element-coded affinity tags

1. A method for detecting oxidation patterns of an oxidized biomolecule, said method comprising:

(a) contacting a biological sample suspected of containing an oxidized biomolecule with a tag moiety comprising a macrocyclic chelating agent complexed to a metal ion, wherein the macrocyclic chelating agent has the formula (Ia):

wherein

each of L 1 , L 2 , L 3 and L 4 are linking groups independently selected from C 2-5 alkylene which is optionally substituted with one to three substituents selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl and substituted and unsubstituted aryl;

each of R N1 , R N2 , R N3 and R N4 are independently selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl and substituted and unsubstituted aryl;

wherein at least one of L 1 , L 2 , L 3 , L 4 , R N1 , R N2 , R N3 and R N4 comprises a functional group that forms a covalent linkage at an oxidized site on said oxidized biomolecule,

thereby forming an adduct between said oxidized biomolecule and said tag moiety;

(b) contacting said adduct with an affinity medium comprising a first binding moiety that binds said tag moiety;

(c) eluting said adduct from said affinity medium, thereby forming a solution comprising said adduct; and

(d) detecting the adduct by detecting the weight of the adduct comprising the metal ion in the tag moiety of step (c), thereby detecting the oxidation pattern of the biomolecule.

2. The method according to claim 1 , wherein said biological sample is isolated from an individual suspected of having a disease selected from the group consisting of: a neurodegenerative disorder, a neoplastic disorder, a vascular disorder, and an autoimmune disorder.

3. The method according to claim 1 , wherein said oxidized biomolecule is selected from the group consisting of: a polypeptide, a lipid, a glycoprotein, and a nucleic acid.

4. The method according to claim 3 , wherein said oxidized biomolecule is a polypeptide.

5. The method according to claim 1 , wherein said metal ion is selected from a lanthanide ion, an actinide ion, an alkaline earth metal ion, a transition metal ion, and a post transition metal ion.

6. The method according to claim 1 , wherein said quantity of said adduct is determined by mass spectrometry.

7. The method according to claim 1 , wherein detecting said oxidized biomolecule detects the quantity of said oxidized biomolecule in said biological sample.

8. The method according to claim 1 , wherein detecting said oxidized biomolecule detects an oxidation site within said oxidized biomolecule in said biological sample.

9. The method according to claim 1 , wherein said macrocyclic chelating agent comprises four nitrogen atoms.

10. The method according to claim 1 , wherein said macrocyclic chelating agent has Formula Ia′:

wherein

Z 1 , Z 2 , Z 3 and Z 4 are members independently selected from OR 1 and NR 1 R 2

in which

R 1 and R 2 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

R 1a and R 4a are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl; substituted or unsubstituted aryl and linker moieties;

wherein at least one of R 1 , R 2 , R 1a , R 4a comprise said functional group; and

d is 1 or 2.

11. The method according to claim 10 , wherein R 1a or R 4a comprises a moiety having Formula (Ia″):

wherein

R 3 , R 4 , R 5 , R 6 and R 7 are members independently selected from H, halogen, NO 2 , CN, X 1 R 8 , NR 9 R 10 , and C(═X 2 )R 11

wherein

X 1 is a member selected from O, NH and S;

R 8 and R 9 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and C(X 3 )R 12

wherein

X 3 is a member selected from O, S and NH;

R 12 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and OR 13

wherein

R 13 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

R 10 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and OH,

and R 9 and R 10 , taken together are optionally (═C═S);

X 2 is a member selected from O, S and NH; and

R 11 is a member selected from H, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, OR 14 , NR 15 R 16

wherein

R 14 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and C(O)R 17

wherein

R 17 is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

R 15 and R 16 are members independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

s is 0, 1, 2, 3, or 4.

12. The method according to claim 1 , wherein said chelating agent is a member selected from substituted or unsubstituted DOTA, and substituted or unsubstituted TETA.

13. The method according to claim 1 wherein said first binding moiety is a polypeptide.

14. The method according to claim 13 , wherein said polypeptide is an antibody.

15. The method according to claim 14 , wherein said antibody specifically binds to a metal chelate.

16. The method according to claim 15 , wherein said antibody comprises a VL and VH chain, wherein the VL chain is selected from the group consisting of SEQ ID NO: 1, 21, 22 and 23 and the VH chain is selected from the group consisting of SEQ ID NO: 5, 9, 10, 11, 12, 13 and 14.

17. The method according to claim 1 , wherein said tag moiety further comprises a second binding moiety that is complementary to said first binding moiety.

18. The method according to claim 17 , wherein said second binding moiety is a polypeptide.

19. The method according to claim 17 , wherein said second binding moiety is biotin.

20. The method according to claim 1 , further comprising detecting the oxidation pattern of said oxidized biomolecule in a second biological sample by

(e) contacting a second biological sample suspected of containing said oxidized biomolecule with a second tag moiety comprising a macrocyclic chelating agent complexed to a second metal ion, wherein the macrocyclic chelating agent comprises a functional group that forms a covalent linkage at an oxidized site on said oxidized biomolecule and wherein the macrocyclic chelating agent has the formula (Ia):

wherein

each of L 1 , L 2 , L 3 and L 4 are linking groups independently selected from C 2-5 alkylene which is optionally substituted with one to three substituents selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl and substituted and unsubstituted aryl;

each of R N1 , R N2 , R N3 and R N4 are independently selected from the group consisting of substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl and substituted and unsubstituted aryl;

wherein at least one of L 1 , L 2 , L 3 , L 4 , R N1 , R N2 , R N3 and R N4 comprises said functional group, thereby forming a second adduct between said oxidized biomolecule and said second tag moiety;

(f) contacting said second adduct with the affinity medium;

(g) eluting said second adduct from said affinity medium, thereby forming a solution comprising said adduct; and

(h) detecting the second adduct by detecting the weight of the second adduct comprising the metal ion in the second tag moiety of step (g), thereby detecting the pattern of oxidation of the biomolecule in the second biological sample.

21. The method according to claim 20 , wherein said first sample and said second sample are isolated from the same individual.

22. The method according to claim 20 , wherein said first sample and said second sample are isolated from an individual suspected of having a disease selected from the group consisting of: a neurodegenerative disorder, a neoplastic disorder, a vascular disorder, and an autoimmune disorder.

23. The method according to claim 20 , wherein said first sample and said second sample are isolated from an individual being treated for a disease selected from the group consisting of: a neurodegenerative disorder, a neoplastic disorder, a vascular disorder, and an autoimmune disorder.

24. The method according to claim 20 , wherein said first sample is isolated from a tissue suspected of being diseased and said second sample is from a nondiseased tissue.

25. The method according to claim 20 , wherein said first metal ion and said second metal ion are members independently selected from a lanthanide ion, an actinide ion, an alkaline earth metal ion, a transition metal ion, and a post transition metal ion.

26. The method according to claim 20 , wherein said quantity of first adduct and said second adduct is determined by mass spectrometry.

27. The method according to claim 19 , wherein said first binding moiety is streptavidin.